发明申请
- 专利标题: QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION
- 专利标题(中): 喹啉酮化合物和药物组合物
-
申请号: US13590227申请日: 2012-08-21
-
公开(公告)号: US20120316168A1公开(公告)日: 2012-12-13
- 发明人: Kenji OTSUBO , Yuji OCHI , Masami NAKAI , Atsushi MORI
- 申请人: Kenji OTSUBO , Yuji OCHI , Masami NAKAI , Atsushi MORI
- 申请人地址: JP Tokyo
- 专利权人: OTSUKA PHARMACEUTICAL CO., LTD.
- 当前专利权人: OTSUKA PHARMACEUTICAL CO., LTD.
- 当前专利权人地址: JP Tokyo
- 优先权: JP2007-150819 20070606
- 主分类号: A61K31/47
- IPC分类号: A61K31/47 ; A61K31/4709 ; C07D215/28 ; C07D409/04 ; C07D403/04 ; C07D401/04 ; C07D413/10 ; A61K31/5377 ; A61P3/04 ; A61P25/28 ; A61P25/16 ; A61P25/00 ; A61P25/14 ; A61P29/00 ; A61P1/00 ; A61P27/16 ; A61P25/24 ; A61P13/12 ; C07D405/04
摘要:
The present invention provides a quinolone compound represented by General Formula (1) or a salt thereof, wherein R1 represents a hydrogen atom, etc.; R2 represents a hydrogen atom, etc.; R3 represents a phenyl group optionally being substituted with one or more substituents, etc.; R4 represents a halogen atom; R5 represents a hydrogen atom or halogen atom; R6 represents a hydrogen atom; and R7 represents a hydroxyl group, etc. The quinolone compound have a functional improvement effect, which suppresses progression of neurological dysfunction by inhibiting the chronic progression of Parkinson's disease or protecting dopamine neurons from the disease etiology, thereby prolonging the period before first administration begins.
公开/授权文献
- US08642619B2 Quinolone compound and pharmaceutical composition 公开/授权日:2014-02-04
信息查询